Table 1.

Comparison of Antifungal Agent Prescription in Relation to Healthcare Network A in Hong Kong^a

Healthcare Network	Relative Risk and 95% Confidence Interval	p value	Remark
Network A	1b	NA	NA
Network B	0.299 (0.272–0.329)	<0.001	70.1% less than network A
Network C	0.225 (0.200–0.253)	<0.001	77.5% less than network A
Network D	0.289 (0.262–0.318)	<0.001	71.1% less than network A
Network E	0.354 (0.325–0.386)	<0.001	64.6% less than network A
Network Fc	0.347 (0.317–0.380)	<0.001	65.3% less than network A
Network Gc	0.460 (0.417–0.508)	<0.001	54.0% less than network A

Notes: ^aThe antifungal agents includes amphotericin B (parenteral), echinocandin [anidulafungin (parenteral), caspofungin (parenteral), micafungin (parenteral)], triazole [fluconazole (oral and parenteral), isavuconazole (oral and parenteral), itraconazole (oral and parenteral), posaconazole (oral and parenteral), voriconazole (oral and parenteral)], and others [5-flucytosine (oral and parenteral), griseofulvin (oral), ketoconazole (oral), miconazole (parenteral), nystatin (oral), terbinafine (oral)]. ^bRelative risk of antifungal agent prescription in network A is set as 1 for calculation. ^cHealthcare network with nosocomial outbreaks of C. auris.

Abbreviation: NA, not applicable.